- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Research progress of antibody–drug conjugates in gynecologic cancer ; volume:3 ; number:1 ; day:29 ; month:8 ; year:2024 ; pages:1-13 ; date:12.2024
Holistic integrative oncology ; 3, Heft 1 (29.8.2024), 1-13, 12.2024
- Urheber
-
Xu, Dongdong
Chen, Zhe-Sheng
Peng, Xuanwei
Lin, Zhongqiu
Lu, Huaiwu
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s44178-024-00114-8
- URN
-
urn:nbn:de:101:1-2411250841299.414798966992
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Xu, Dongdong
- Chen, Zhe-Sheng
- Peng, Xuanwei
- Lin, Zhongqiu
- Lu, Huaiwu
- SpringerLink (Online service)
Ähnliche Objekte (12)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Antibody–drug conjugates as an emerging therapy in oncodermatology
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates